6533b7ddfe1ef96bd12746d2

RESEARCH PRODUCT

Blood Flow, Vascular Resistance and Oxygen Availability in Malignant Tumours upon Intravenous Flunarizine

Peter VaupelH. Menke

subject

business.industryAntagonistCancerchemistry.chemical_elementBlood flowCalciumPharmacologymedicine.diseasemedicine.anatomical_structureBlood pressurechemistryCancer cellmedicineVascular resistancebusinessFlunarizinemedicine.drug

description

Tumour blood flow, an important determinant of the efficacy of presently available nonsurgical cancer treatments, significantly increased following a single I.V. injection of the calcium antagonist flunarizine. At a dose of 1 mg/kg, tumour blood flow increased approximately by 28% without a significant change in mean arterial blood pressure. The flow increase was paralleled by a similar improvement of the O2 availability to the cancer cells. The data suggest that flunarizine may provide a means of improving delivery of antineoplastic agents to tumours. Furthermore, flunarizine may also enhance the effectiveness of irradiation by increasing tumour oxygenation.

yearjournalcountryeditionlanguage
1987-01-01
https://doi.org/10.1007/978-1-4684-7433-6_48